Table 13.
Percentage of DC subsets and expression of costimulatory and LNH molecules in the circulation of women with LLABCs.
| mDC1s and pDCs | % of subsets and costimulatory molecules in women with LLABCs (n = 30) | % of subsets and costimulatory molecules in HFDs (n = 10) | p value |
|---|---|---|---|
| Lin1−, HLA-DR+ DCs | 1.26 ± 0.20 | 1.70 ± 0.30 | 0.034∗ |
| mDC1high (Lin1−, HLA- DR+, CD11c+CD1c+) | 0.10 ± 0.04 | 0.15 ± 0.05 | 0.045∗ |
| pDChigh (Lin1−, HLA-DR+, CD11c+CD303+) | 0.03 ± 0.02 | 0.06 ± 0.02 | 0.041∗ |
| mDC1 HLA-DR+ | 47.30 ± 8.00 | 65.00 ± 3.10 | 0.045∗ |
| pDC HLA-DR+ | 48.12 ± 9.50 | 65.52 ± 5.00 | 0.002∗ |
| mDC1 CD40+ | 35.01 ± 8.00 | 44.87 ± 6.50 | 0.011∗ |
| mDC1 CD80+ | 1.40 ± 0.60 | 1.87 ± 0.35 | NS |
| mDC1 CD83+ | 3.18 ± 0.40 | 4.04 ± 0.30 | 0.047∗ |
| mDC1 CD86+ | 28.56 ± 3.00 | 34.07 ± 8.00 | NS |
| mDC1 CD197+ | 20.35 ± 4.50 | 24.68 ± 9.00 | NS |
LNH: lymph node homing; LLABCs: large and locally advanced breast cancers; mDC1: myeloid dendritic cell; pDC: plasmacytoid dendritic cell; HFDs: healthy female donors; NS: nonsignificant; ∗statistically significant.